



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

## Operations Office

---

Date: March 2, 2007

To: NCCTG Primary Clinical Research Associates

From: Laura Denton, Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR<sup>®</sup> Depot) for Symptomatic Ascites in Cancer Patients

The MCLCT fax supply order form has been revised so now the “Main Member Principal Investigator” is not required to be listed.

If you have any questions, please feel free to contact me at 507/538-1802.

Thank you.